Generation Bio Co. Statistics
Total Valuation
GBIO has a market cap or net worth of $242.16 million. The enterprise value is $116.62 million.
| Market Cap | 242.16M |
| Enterprise Value | 116.62M |
Important Dates
The last earnings date was Monday, May 13, 2024, after market close.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GBIO has 66.53 million shares outstanding. The number of shares has increased by 10.30% in one year.
| Shares Outstanding | 66.53M |
| Shares Change (YoY) | +10.30% |
| Shares Change (QoQ) | +0.54% |
| Owned by Insiders (%) | 14.56% |
| Owned by Institutions (%) | 83.30% |
| Float | 48.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 24.31 |
| Forward PS | 37.05 |
| PB Ratio | 1.83 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.01, with a Debt / Equity ratio of 0.73.
| Current Ratio | 8.01 |
| Quick Ratio | n/a |
| Debt / Equity | 0.73 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -82.30% and return on invested capital (ROIC) is -79.55%.
| Return on Equity (ROE) | -82.30% |
| Return on Assets (ROA) | -46.70% |
| Return on Capital (ROIC) | -79.55% |
| Revenue Per Employee | $57,259 |
| Profits Per Employee | -$971,603 |
| Employee Count | 174 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.65% in the last 52 weeks. The beta is 2.87, so GBIO's price volatility has been higher than the market average.
| Beta (1Y) | 2.87 |
| 52-Week Price Change | -12.65% |
| 50-Day Moving Average | 3.36 |
| 200-Day Moving Average | 2.77 |
| Relative Strength Index (RSI) | 57.84 |
| Average Volume (30 Days) | 244,998 |
Short Selling Information
The latest short interest is 1.75 million, so 2.63% of the outstanding shares have been sold short.
| Short Interest | 1.75M |
| Short Previous Month | 1.58M |
| Short % of Shares Out | 2.63% |
| Short % of Float | 3.60% |
| Short Ratio (days to cover) | 7.22 |
Income Statement
In the last 12 months, GBIO had revenue of $9.96 million and -$169.06 million in losses. Loss per share was -$2.55.
| Revenue | 9.96M |
| Gross Profit | 9.96M |
| Operating Income | -181.33M |
| Pretax Income | -169.06M |
| Net Income | -169.06M |
| EBITDA | -163.81M |
| EBIT | -169.06M |
| Loss Per Share | -$2.55 |
Balance Sheet
The company has $221.49 million in cash and $95.95 million in debt, giving a net cash position of $125.54 million or $1.89 per share.
| Cash & Cash Equivalents | 221.49M |
| Total Debt | 95.95M |
| Net Cash | 125.54M |
| Net Cash Per Share | $1.89 |
| Equity / Book Value | 131.99M |
| Book Value Per Share | 1.98 |
| Working Capital | 198.54M |
Cash Flow
In the last 12 months, operating cash flow was -$56.77 million and capital expenditures -$8.56 million, giving a free cash flow of -$65.33 million.
| Operating Cash Flow | -56.77M |
| Capital Expenditures | -8.56M |
| Free Cash Flow | -65.33M |
| FCF Per Share | -$0.98 |
Margins
Gross margin is 100.00%, with operating and profit margins of -1,820.04% and -1,696.87%.
| Gross Margin | 100.00% |
| Operating Margin | -1,820.04% |
| Pretax Margin | -1,696.87% |
| Profit Margin | -1,696.87% |
| EBITDA Margin | -1,644.22% |
| EBIT Margin | -1,696.87% |
| FCF Margin | -655.68% |
Dividends & Yields
GBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.30% |
| Shareholder Yield | -10.30% |
| Earnings Yield | -69.81% |
| FCF Yield | -26.98% |
Analyst Forecast
The average price target for GBIO is $8.00, which is 118.58% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.00 |
| Price Target Difference | 118.58% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 2.66% |
| EPS Growth Forecast (5Y) | -9.09% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GBIO has an Altman Z-Score of -3.3 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.3 |
| Piotroski F-Score | 1 |